Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Featured trial
Vigor and the LDR in Parkinson Disease Test  

Parkinson disease (PD) is a common disorder in which reduced speed of movement results from inadequate brain production of the chemical dopamine. The most effective treatment for PD is the drug levo-dopa, which partially replaces brain dopamine. Despite decades of successful use, how levo-dopa improves speed of movement in PD …

  • 0 views
  • 13 Nov, 2024
  • 2 locations
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa (Baby-COMET)

This is a single group, treatment, Phase 3, open-label study to assess efficacy, safety, pharmacokinetic (PK), pharmacodynamics (PD) of avalglucosidase alfa in treatment-naïve male and female participants with IOPD. Study details include: Study duration: Screening - up to 4 weeks; Primary Analysis Period (PAP) - 52 weeks; Extended Treatment Period …

  • 0 views
  • 19 Jul, 2024
  • 4 locations
A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV

Many people living with HIV (PLWH) smoke. Smoking in these individuals is often undertreated. This study plans to assess the ability of various clinical pathways involving tobacco treatment medications and contingency management (paying smokers for not smoking) to improve smoking cessation in a group of PLWH.

smoking cessation therapy
tobacco use disorder
  • 0 views
  • 05 Aug, 2020
Randomised Evaluation of COVID-19 Therapy (RECOVERY)  

RECOVERY is a randomised trial investigating whether treatment with Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Infliximab, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only) prevents death in patients with COVID-19.

  • 0 views
  • 14 Sep, 2022
  • 6 locations
The Positively Quit Trial for Smoking Cessation

People in both groups will receive brief advice to quit and an offer of nicotine replacement therapy patches (NRT), as well as 12 videoconferencing group sessions. We will measure smoking behavior over a one year period and compare smoking rates for the treatment condition against AMC to see if the …

  • 0 views
  • 16 Feb, 2024
  • 1 location
Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients

Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive …

heart surgery
cognitive deficits
thoracotomy
cognitive impairment
coronary artery bypass graft
  • 0 views
  • 16 Feb, 2024
  • 1 location
Randomised Evaluation of COVID-19 Therapy

RECOVERY is a randomised trial investigating whether treatment with either Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Convalescent plasma or Tocilizumab prevents death in patients with COVID-19.

covid-19
iv immunoglobulin
colchicine
hydroxychloroquine
tocilizumab
  • 0 views
  • 05 Aug, 2020
Liberation From Acute Dialysis

The goal of the LIBERATE-D clinical trial is to improve outcomes for patients recovering from dialysis-requiring acute kidney injury (AKI-D). The impact of a conservative dialysis strategy compared to standard clinical practice of thrice-weekly dialysis will be examined to help generate knowledge for how to guide delivery of dialysis to …

liberate
acute renal failure
renal injury
acute tubular necrosis
injury kidney
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Pompe Disease Registry

The objectives of the Registry are: To enhance the understanding of the variability, progression, and natural history of the key manifestations of Pompe disease; To assist the Pompe medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care; To characterize …

myozyme
glycogen storage disease type ii
gaa gene
deficiency
replacement therapy
  • 0 views
  • 22 Dec, 2020
  • 169 locations
Mucopolysaccharidosis I (MPS I) Registry

The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: …

  • 0 views
  • 04 Dec, 2020
  • 125 locations